U.S., Aug. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07148557) titled 'A Study of Single Dose of LP-003 in Adolescent Subjects' on Aug. 15.
Brief Summary: This is a single-center, open-label, phase Ib clinical study to evaluate the safety, pharmacokinetics and pharmacodynamic characteristics of LP-003 injection in adolescent subjects aged 12-18 years.
Study Start Date: Aug. 31
Study Type: INTERVENTIONAL
Condition:
Chronic Spontaneous Urticaria (CSU)
Seasonal Allergic Rhinitis (SAR)
Intervention:
BIOLOGICAL: LP-003 Dose 1 (Single)
A single dose of LP-003 (400 mg/dose) was SC
BIOLOGICAL: LP-003 Dose 2 (Single)
A single dose of LP-003 (600 mg/dose) was SC
Recruitment Status: NOT_YET_RECRUITING
...